IkB-ζ signaling promotes chondrocyte inflammatory phenotype, senescence, and erosive joint pathology

Manoj Arra1, Gaurav Swarnkar1, Yael Alippe2, Gabriel Mbalaviele2 and Yousef Abu-Amer3

Osteoarthritis is a joint disease characterized by a poorly-defined inflammatory response that does not encompass a massive immune cell infiltration yet contributes to cartilage degradation and loss of joint mobility, suggesting a chondrocyte intrinsic inflammatory response. Using primary chondrocytes from joints of osteoarthritic mice and patients, we first show that these cells express ample pro-inflammatory markers and RANKL in an NF-κB dependent manner. The inflammatory phenotype of chondrocytes was recapitulated by exposure of chondrocytes to IL-1β and bone particles, which were used to model bone matrix breakdown products revealed to be present in synovial fluid of OA patients, albeit their role was not defined. We further show that bone particles and IL-1β can promote senescent and apoptotic changes in primary chondrocytes due to oxidative stress from various cellular sources such as the mitochondria. Finally, we provide evidence that inflammation, oxidative stress and senescence converge upon IkB-ζ, the principal mediator downstream of NF-κB, which regulates expression of RANKL, inflammatory, catabolic, and SASP genes. Overall, this work highlights the capacity and mechanisms by which inflammatory cues, primarily joint degradation products, i.e., bone matrix particles in concert with IL-1β in the joint microenvironment, program chondrocytes into an "inflammatory phenotype" which inflicts local tissue damage.

Bone Research (2022) 10:12 ; https://doi.org/10.1038/s41413-021-00183-9

INTRODUCTION

Osteoarthritis (OA) is the most prevalent joint disease worldwide, causing pain, decreased quality of life, and reduced productivity in those affected by this condition. However, current OA treatment regimens do not contain any disease-modifying therapeutics but instead rely upon symptom-reducing compounds, though promising advancements have been made in the field. Given the prevalence of this disease, novel targets and therapeutics are greatly needed to combat the impact of OA on patients and society.

While OA was traditionally considered as non-inflammatory arthritis, extensive work has displayed the role of inflammation in OA. Inflammation is induced by many processes, ranging from mechanical stress to stimulation by inflammatory cytokines, all of which play a role in the initiation and propagation of this disease. It is likely that OA is induced by various acute inflammatory insults throughout life, such as mechanical injury, which then contribute to a sustained chronic, inflammatory state as patients grow older. The response of articular chondrocytes to these inflammatory stimuli contributes to the development and progression of OA by promoting the expression of catabolic factors that break down ECM that normally gives cartilage its joint protective properties. Furthermore, the role of senescent chondrocytes in articular cartilage as a source of pro-inflammatory factors has been highlighted in recent years, primarily due to the production of senescence-associated secretory phenotype (SASP) factors that are pathogenic. This can lead to a positive feedback cycle of chronic inflammation through autocrine and paracrine effects. Although it is still unclear what drives chondrocyte senescence, some possibilities include factors such as oxidative stress, microRNAs, and inflammatory pathways. Oxidative and nitrosative stresses have especially gained interest because they can arise from multiple components within the cell and are intrinsically related to inflammation and cellular metabolism. Reactive oxygen species such as superoxide can damage DNA, proteins, and lipids to alter cellular physiology and promote pathology. It is predicted that prevention of senescence or reduction of SASP expression from senescent chondrocytes, which overlaps with the inflammatory response, may be important for reducing the chronic inflammatory state of OA joints and prevent OA progression.

The role of cartilage and bone degradative by-products in OA disease pathology is also an area that requires further research. The presence of calcium crystals and other by-products of bone and ECM degradation has been noted in the synovial fluid of OA joints, with some groups suggesting that these particles are pro-pathogenic while others suggest that they are merely by-products of disease. The source of these particles is still unknown, though it is predicted to be from a combination of cartilage calcification by hypertrophic chondrocytes, bone erosion of juxta-articular regions, or bone-on-bone erosions. Even in the setting of bone-on-bone erosion or internal knee injuries that release bone fragments, cartilage remains present in the joint, and understanding the function of these complex bone particles (BP) on the remaining joint health needs to be elucidated, especially if future therapies aim to focus on cartilage regeneration. One of the major findings in OA patients is the alteration of subchondral bone physiology and structure, leading to the prediction that
interaction between articular cartilage and subchondral bone cells is important for OA pathogenesis.  

Subchondral bone sclerosis and osteophyte formation late in OA is characteristic of the disease, though it is unclear if early OA has similar findings and should be further explored. It is possible that altered catabolism of subchondral bone may be a contributor to the presence of crystals in the synovial space, especially by osteoclast activity promoted by chondrocytes. Previous reports indicate that crystal fragments and crystals can be pathological, with some animal studies suggesting that these particles contribute to the chronic inflammatory state of OA synovial joints. The goal of this work is to explore the effects of pathogenic molecular entities and associated inflammatory signals, such as BP and IL-1β, on chondrocytes and the downstream mediators involved. In this work, we display that chondrocytes can support osteoclast formation in response to inflammatory stimuli through increased Rankl production. Furthermore, we show that bone matrix particles are highly pro-inflammatory and can synergize with inflammatory cytokines to drive catabolic enzyme expression in an NF-κB dependent manner. We also display that inflammatory stimuli can promote senescent and apoptotic changes. Finally, we show that BP and IL-1β act via IkB-ζ to promote SASP expression in a manner dependent upon oxidative and nitrosative stresses.

RESULTS

OA joints have increased osteoclast activity and Rankl production by chondrocytes.

It has been noted that joints likely undergo erosive changes during the early stages of OA, followed by subchondral sclerosis in advanced stages. We surmised that the local joint microenvironment supports bone and cartilage erosion through elevated osteoclast activity, contributing to subchondral changes. Hence, we set out to determine if OA chondrocytes in humans and murine models display increased receptor activator of NF-κB ligand (Rankl) expression, the critical factor required for osteoclastogenesis. We utilized the well-established meniscal ligamentous injury (MLI) model to provoke experimental OA in mice and observed that cartilage from MLI joints after surgery had elevated levels of Rankl (Tnfsf11) mRNA expression compared to sham surgery joints (Fig. 1a). We also observed similar changes in human OA cartilage when comparing more damaged medial cartilage to relatively healthy lateral cartilage in patients with medial compartment OA (Fig. 1b). Since we have recently shown that inflammation is a significant driver of OA joint degeneration, we treated mouse-derived chondrocytes with IL-1β, a major inflammatory mediator and marker of OA. We observed that exposure of chondrocytes to IL-1β significantly increased the expression ofRankl mRNA and Rankl protein secretion (Fig. 1c, d). Furthermore, we have previously demonstrated in articular chondrocytes that NF-κB activation, the principle inflammatory response pathway, is a critical component of OA pathogenesis and predicted that the increase in Rankl expression is mediated via NF-κB activation. Confirming this proposition, we show that NF-κB activation using the constitutively active form of IKK2 (IKK2ca) also drives Rankl expression mimicking inflammatory stimuli (Supplementary Fig. S1a). This was further validated using the IKK2 inhibitor, SC-514, which reduced Rankl expression in IL-1β-treated chondrocytes (Fig. 1c). Since osteoprotegerin (Opg) is also an important counterpart to Rankl in modulating osteoclastogenesis by negatively regulating osteoclast formation, we sought to determine the Rankl:Opg ratio. We observed that IL-1β treatment decreased Opg mRNA expression (Supplementary Fig. S1b) and greatly increased the Rankl:Opg ratio but the application of IKK2 inhibitor reduced the Rankl:Opg ratio through both reduction in Rankl and increase in Opg mRNA expression (Supplementary Fig. S1c).

Consistent with these observations, we predicted that chondrocytes may be an important source of Rankl near damaged cartilage. We first tested whether the presence of Rankl in the synovial fluid can promote subchondral osteoclast formation. Recombinant Rankl was injected into the synovial space by intra-articular injection, with PBS injection used as control. Rankl injection into the synovial space led to a dramatic increase in osteoclasts in the subchondral region (Supplementary Fig. S1d, e). We then proposed that post-surgery MLI joints displayed increased tartrate-resistant acid phosphatase (TRAP)-positive staining in the anterior femoral subchondral bone region compared to contralateral sham joints, indicating increased osteoclast activity and altered bone resorption (Fig. 1e, f). However, we did not observe statistically significant differences in osteoclast number in the tibial regions or posterior femoral regions. When analyzed by μCT, MLI joints in mice (Supplementary Fig. S1g) at 2 weeks post-surgery have increased bone erosion and subchondral bone loss compared to sham joints as measured by subchondral bone volume (Fig. 1g, h, Supplementary Fig. S1f). We also utilized the Aggrecan-ERT2-cre IKK2ca (AcamIKK2ca) mouse model, which displays IKK2 activation in articular chondrocytes, that we have previously shown can drive cartilage degradation and mimic an OA-like phenotype. These joints also have decreased joint spacing and blunting of the bony surfaces in the subchondral region similar to post-traumatic OA even in the absence of mechanical injury (Supplementary Fig. S1i). This suggests that chondrocyte-specific NF-κB activity can cause bone degradation and modify the subchondral region, potentially via Rankl expression and altered mechanical properties of the joint due to cartilage degradation.

To substantiate our observations, we sought to determine if chondrocytes can directly promote osteoclast formation and regulate bone degradation. We utilized a chondrocyte-macrophage co-culture system to allow for the interaction of chondrocyte-secreted factors with bone marrow macrophages to determine the effect on osteoclast differentiation. At basal conditions, chondrocytes co-cultured with macrophages did not increase the presence of TRAP positive cells compared to macrophages in culture alone since chondrocytes produce significant amounts of Opg under physiologic conditions. Given that chondrocytes treated with IL-1β had increased expression of Rankl, we then asked if under inflammatory conditions, chondrocytes could support and promote osteoclastogenesis. We show that macrophage-to-chondrocyte co-cultures treated with IL-1β had increased TRAP positive cells compared to those without IL-1β in the presence of permissive levels of exogenous Rankl, which was added to prime commitment of monocytic/macrophage into OC precursors (Fig. 2a, b). We confirmed this to be a chondrocyte-mediated effect by comparing co-cultures using IKK2 deficient chondrocytes treated with IL-1β and Rankl, which displayed significantly less TRAP positive multi nucleated cells (Fig. 2a, b; right panels). This finding suggests that IKK2 mediates the IL-1β inflammatory response of chondrocytes to produce Rankl and enhance osteoclastogenesis (Fig. 2a, b). Mirroring these findings, we observed that chondrocyte-macrophage co-cultures had significantly higher TRAP expression when treated with IL-1β compared to macrophages treated with IL-1β alone, suggesting that chondrocytes can support macrophage differentiation into osteoclasts under inflammatory conditions (Fig. 2c).

Bone tissue particles are potent pro-inflammatory molecules that act in an NF-κB dependent manner. We then proposed that joint pathology is exacerbated by cartilage and bone mineral particles, released into the synovial space from various factors such as cartilage calcification, osteoclast resorption, and mechanical cartilage-bone erosion, which could act as pro-inflammatory mediators. These inert particles likely act in a pro-inflammatory manner to drive cartilage degradation based on...
findings from prior work studying inert crystals. Given the principal role of NF-κB as the major inflammatory response pathway, we predicted that bone matrix particles would activate this pathway. Since mineralized bone degradation products cannot be isolated from the joint fluid of mouse joints due to the small volume, we used BP as surrogates for proof-of-concept studies. BP were generated by grinding the cortical surface of porcine long bones, rinsed repeatedly in sterile PBS, and stored in...
70% ethanol. These BP were then washed again with PBS before addition to cultures. We established that, similar to IL-1β, treatment of chondrocytes with BP potently activates NF-κB (Fig. 3a). BP were also able to activate expression of pathological inflammatory response genes including IL-6 and MMP13 (Fig. 3b, c). Furthermore, we show that BP are able to synergize with constitutively active IKK2 (IKK2ca) to increase the expression of Il-6, Mmp13 and Adamts4 (Supplementary Fig. S2a–c) akin to exacerbated disease conditions, relative to IKK2ca alone. To substantiate our claim that BP act via NF-kB, we tested if inhibition of NF-kB would be sufficient to prevent the inflammatory response induced by BP. We showed that genetic ablation of IKK2, the major NF-kB activating kinase, in chondrocytes led to significant reduction in inflammatory gene expression with BP treatment (Fig. 3b, c). We also utilized a kinase-dead form of IKK2 (IKK2-KD) that has a dominant-negative effect to show that it was able to prevent the inflammatory response induced by BP by preventing signal transduction through IKK2 (Supplementary Fig. S2d–f). Overall, these results suggest that BP can promote a strong inflammatory response causing catabolic changes in an NF-kB dependent manner.

Given the potent role of NF-kB in the IL-1β and BP inflammatory response, we sought to define if the anti-inflammatory effect of IKK2 inhibition observed in vitro could be translated in vivo to protect against OA. We injected mice with IKK2 inhibitor (IKK2i) systemically for 6 weeks post MLI surgery and observed a significant increase in cartilage integrity and improved OARSI scoring in MLI joints of IKK2i-treated animals (Fig. 3d, e). In addition, there was significantly decreased staining for MMP13 in the articular cartilage of IKK2i-treated MLI joints, indicating decreased catabolic activity (Fig. 3f; arrows).

Fig. 2  Chondrocytes support osteoclastogenesis under inflammatory conditions.  a Primary IKK2f/f chondrocytes were isolated and infected with adenoviral-GFP or adenoviral-cre to delete IKK2. Bone marrow macrophages were then added to the culture. Permissive levels of Rankl (5 ng·mL−1) was added ± IL-1β (10 ng·mL−1) for 3 days. Cultures were fixed and stained for TRAP positive osteoclasts (red arrows). Macrophages alone cultures are displayed as control. b Number of large, multi nucleated cells (MNC) in macrophage-chondrocyte co-culture were quantified by counting. (WT + IL-1β vs IKK2−/− + IL-1β ***P = 0.0002, n = 4 wells from representative experiment). Bars represent mean ± S.D. c mRNA was isolated from co-cultures of chondrocytes and macrophages ± IL-1β. Gene expression analysis was performed for TRAP (**P = 0.0017, n = 4). Bars represent mean ± S.D.
Bone particles activate NLRP3 inflammasome and IκB-ζ in chondrocytes

We sought to further characterize the mechanism(s) underlying the response to BP exposure to identify potential therapeutic targets. Given that BP are not a signaling protein per se, we suspected that they may act as damage-associated molecular pattern (DAMP) molecules to stimulate the expression of inflammatory genes including Nlrp3, which assembles an inflammasome involved in the maturation of IL-1β, as well as the regulation of various intracellular processes such as apoptosis.37 We observed that BP treatment increases expression of Nlrp3 at both the gene and protein level (Fig. 4a, b). Furthermore, damaged human cartilage has elevated levels of NLRP3 gene expression compared to healthier cartilage (Fig. 4c), suggesting...
Fig. 4 Bone particles promote inflammation via NLRP3 and IkB-ζ activity. a Primary chondrocytes were cultured with BP for 24 h and Nlrp3 gene expression was measured (**P = 0.0009). Bars represent mean ± S.E.M from n = 4 independent experiments. b Immunoblotting was performed for Nlrp3 protein using chondrocytes lysates under BP treatment time course, with actin loading used as control. The representative image is shown. c Relative mRNA expression was measured (***P < 0.0001). Bars represent mean ± S.D. from four independent experiments. d, e Cells were treated with IL-1β or BP for 24 h and IL-1β gene expression was measured. Bars are mean ± S.D from n = 6 independent experiments. f Cells were retroviral transduced with GFP or IKK2ca, then treated with bone particles for 24 h. Supernatant was collected and ELISA was performed for IL-1β levels (GFP vs IKK2ca + BP **P = 0.0018, n = 4 replicates). g, h Chondrocytes isolated from WT or Nlrp3-deficient mice and treated with BP for 24 h. IL-6 and Mmp13 gene expression measured by qPCR (IL-6: WT + BP vs Nlrp3−/− + BP 4****P < 0.0001; Mmp13: WT + BP vs Nlrp3−/− + BP 4****P < 0.0001). Bars are mean ± SD for n = 4 replicates. i Primary chondrocytes were treated with BP for 24 h. Nfkbi expression was measured by qPCR (**P = 0.0187). Bars are mean ± S.E.M for n = 4 independent experiments. j Chondrocytes were exposed to IL-1β and/or bone particles. Lysates were collected and Immunoblotting was performed for IkB-ζ. Representative immunoblot is shown. k–n Nfkbi floss chondrocytes were transduced with adenovirus (WT) or adenovirus (Nfkbi−/−). Cells were then treated with BP ± IL-1β. Gene expression of IL-6, Mmp13, Nlrp3 and Rankl was measured by qPCR (IL-6: GFP + BP vs Nfkbi−/− + BP **P = 0.0029; GFP + BP + IL-1β vs Nfkbi−/− + BP + IL-1β 4****P < 0.0001; Mmp13: GFP + BP vs Nfkbi−/− + BP 4****P < 0.0001; Rankl: GFP + BP vs Nfkbi−/− + BP 4****P < 0.0001). Bars represent mean ± S.D. from one representative experiment out of three.
that the NLRP3 inflammasome may be involved in the human disease.

We then displayed that IL-1β and BP treatment can both drive gene expression of IL-1β itself (Fig. 4d, e). The ability of IL-1β to induce its own expression suggests a feedforward pro-inflammatory mechanism by which chondrocytes can propagate inflammation in a paracrine or even autocrine manner. In agreement with our hypothesis that BP can act as DAMP signals that promote Nlrp3 activity, we observed that BP treatment of chondrocytes expressing Ikk2ca significantly increased chondrocyte secretion of IL-1β, whereas individual treatment of chondrocytes with BP or Ikk2ca expression alone is not a potent activator of IL-1β secretion (Fig. 4f). This suggests that NF-kB activation likely acts as a primary signal to promote Nlrp3 expression while BP act as the secondary signal for Nlrp3 assembly and activation. We also observe that Nlrp3-deficient chondrocytes have reduced Il-6 and Mmp13 expression upon bone particle treatment (Fig. 4g, h).

However, given that the inhibition of inflammatory gene expression resulting from Nlrp3 deletion was only partial, we sought to identify a factor further upstream that can be a more potent activator of this inflammatory response. Our previous work has displayed that incubation of chondrocytes with IL-1β increased gene expression of Nfkбiz, which encodes for ikb-ζ, a pro-inflammatory mediator. Furthermore, we have recently shown that ML1 joints in mice and damaged cartilage from humans have elevated expression of Nfkбiz in the articular cartilage. Our work, and that of others, has displayed that ikb-ζ is a prominent pro-inflammatory secretome in OA chondrocytes and is necessary for the expression of various inflammatory and catabolic genes. To this end, treatment of chondrocytes with BP increased the expression of Nfkбiz at the gene level and ikb-ζ at the protein level (Fig. 4i, j). Combined BP and IL-1β treatment further increased protein levels of ikb-ζ (Fig. 4j). Supporting its direct role in this inflammatory response, treatment of Nfkбiz−/− chondrocytes with BP failed to elicit a meaningful inflammatory response compared to wild type chondrocytes, even in the presence of an intact NF-kB signaling pathway (Fig. 4k, l). In addition, we observed that deletion of ikb-ζ decreased expression of Nlrp3 (Fig. 4m), indicating that ikb-ζ is upstream of inflammation-related gene expression. We also observed that deletion of ikb-ζ decreased the expression of Rankl by BP or IL-1β-stimulated chondrocytes (Fig. 4n). Collectively, these findings suggest that under pathologic conditions, ikb-ζ appears to centrally control the expression of inflammatory, catabolic and osteoclastogenic factors.

Inflammatory stimuli promote chondrocyte senescence
Recent reports have proposed that chondrocyte senescence plays a crucial part in OA pathogenesis and we suspected that inflammatory stimuli may contribute to chondrocyte senescent transformation. Thus, we screened RNA sequencing dataset from IL-1β-treated chondrocytes to determine how inflammatory stimuli affect gene expression, wherein we observed that apoptotic and senescence pathways are significantly altered (Table 1).

Next, we examined if inflammatory stimuli were responsible for promoting cellular senescence. BP or IL-1β treatment increased gene expression of cell cycle inhibitors p16 and p21, which are well-established senescence markers (Fig. 5a–d). We focused further on p16 since it has been shown to be important in senescent OA chondrocytes, made evident by the protection of p16-deficient mice against experimental OA development. Gene expression findings were supported by increased protein levels of p16 upon both IL-1β and BP treatment (Fig. 5e). We also observed increased gene expression of P16 in damaged compared to undamaged human OA cartilage (Fig. 5f), and increased staining for p16 in OA cartilage (medial condyle) compared to healthy cartilage (lateral condyle) (Fig. 5g). In addition, we show that IL-1β and BP promote the expression of SASP genes Il-6, Lcn2, and Mmp13 (Supplementary Fig. S3a–f). Furthermore, we show that treatment with a well-established senolytic combination of dasatinib and quercetin (D + Q)44 was able to significantly reduce expression of SASP factors Il-6, Mmp13, and Lcn2 induced by IL-1β or BP treatment (Supplementary Fig. S3a–f). D + Q combination was also able to partially reverse the decreased expression of aggrecan caused by inflammatory stimuli (Supplementary Fig. S3g). Primers used for all genes are listed in Table 2.

Suspecting that the senescent shift was occurring due to NF-kB activity, we show that chondrocytes expressing Ikk2ca also had increased expression of p16 (Fig. 5h). In addition, mice expressing Ikk2ca in chondrocytes (Acaniffkбiz−/−) display increased p16 expression in the articular cartilage compared to wild type mice (Fig. 5i). Validating these findings, inhibition of NF-κB through deletion of Ikk2 was able to decrease the expression of p16 and p21 in response to SP stimulation (Fig. 5j, k). This effect was also seen at the protein level, where deletion of Ikk2 almost completely inhibited expression of p16 (Fig. 5e). This suggests that NF-kB activity is at least partially a driver of p16-mediated senescent changes in addition to acting as a driver of SASP gene expression. Since deletion of NF-kB is often detrimental to cell survival, we compared the transcriptome of IL-1β-treated ikб-ζ deficient (Nfkбiz−/−) chondrocytes to IL-1β-treated wild type chondrocytes and observed that ikб-ζ deletion decreased expression of many SASP factors associated with senescent chondrocytes (Fig. 6a). We then validated these results by qPCR for SASP genes such as Lcn2 and Nos2 to display that ikβ-ζ is the principal mediator of inflammation-induced chondrocyte SASP expression downstream of NF-kB (Fig. 6b, c). However, ikβ-ζ deletion did not modulate expression of senescence markers, such as p16 and p21 (Supplementary Fig. S3h, i). Taken together, our data display that ikβ-ζ is the central inflammatory mediator responsible for SASP, while NF-kB separately regulates both SASP and senescent marker changes.

Inflammatory stimuli promote oxidative stress in chondrocytes to express ikβ-ζ and SASP
We then sought to identify a therapeutic target that was driving the expression of ikβ-ζ. We have previously shown that ikβ-ζ is redox sensitive, with increased cellular ROS causing higher protein expression of ikβ-ζ and sought to determine if IL-1β

| Pathway                                      | P-value  |
|----------------------------------------------|----------|
| Regulation of cell proliferation            | 1.55E-13 |
| Cellular response to DNA damage stimulus    | 1.23E-12 |
| Positive regulation of apoptotic process    | 2.63E-10 |
| Apoptotic process                           | 8.49E-09 |
| Intrinsic apoptotic signaling pathway in response to DNA damage | 1.17E-06 |
| Regulation of apoptotic process             | 3.66E-06 |
| Intrinsic apoptotic signaling pathway in response to oxidative stress | 8.66E-05 |
| Extrinsic apoptotic signaling pathway       | 2.46E-04 |
| Positive regulation of cell death           | 1.63E-03 |
| Positive regulation of cell cycle arrest    | 3.54E-03 |
| Apoptotic mitochondrial changes              | 8.60E-03 |
| Cellular senescence                         | 1.49E-02 |
| Replicative senescence                      | 3.90E-02 |

Table 1. Chondrocytes were treated with IL-1β for 24 h. RNA sequencing was performed and significantly altered pathways are displayed.

M Arra et al.
Fig. 5  Inflamatory mediators promote senescent changes in chondrocytes. a–d Chondrocytes were exposed to BP or IL-1β for 24 h. Gene expression analysis was performed for \( p16 \) or \( p21 \) (A: \( p16: * P = 0.051 \) 1, B: \( p21: * P = 0.022 \) 9, C: \( p16: ** P = 0.009 \) 6, D: \( p21: ** P = 0.003 \) 9). Bars represent mean ± SEM for \( n = 5 \) independent experiments. e Adeno-GFP or adeno-cre were transduced into IKK2−/− chondrocytes. Cells were then treated with BP and/or IL-1β for 24 h. After 24 h, protein lysates were collected and immunoblotting was performed for p16-Ink4a. Representative immunoblot image is shown. f Medial and lateral knee articular cartilage was isolated from patients undergoing TKR with medial compartment OA. P16 gene expression was measured by qPCR \( (P = 0.053) \) 0. Bars are mean ± SD for \( n = 9 \) patients. g Medial and lateral knee articular cartilage was isolated from patients undergoing TKR with medial compartment OA. Cartilage tissue was sectioned and IHC was carried out for p16-Ink4a. Image is representative of \( n = 4 \) healthy and diseases cartilage sections. h GFP or IKK2ca were retrovirally transduced into chondrocytes. p16 expression was measured by qPCR \( (* P = 0.012) \) 2. Bars are mean ± SD from \( n = 4 \) independent experiments. i IKK2ca was expressed in chondrocytes of adult mice in vivo under the control of the tamoxifen inducible aggrecan-cre (AcanIKK2ca). Six weeks post induction, mice were sacrificed and joints were embedded in paraffin and sectioned. IHC was performed for p16, with dark stain representing p16 positive cells. Representative images are displayed. j, k IKK2−/− chondrocytes were transduced with adeno-GFP or adeno-cre. Cells were then treated with BP for 24 h and \( p16 \) and \( p21 \) gene expression was measured \( (p16: * P = 0.021 \) 2, \( n = 2 \), \( p21: ** P = 0.001 \) 7, \( n = 4 \)). Bars represent mean ± SD from representative experiment.
and BP were drivers of oxidative stress. NOX enzymes are a major cause of reactive oxygen species (ROS) upon inflammatory stimulation of chondrocytes, but unlikely to be the only source. Mitochondria are major ROS producers, especially when there is mitochondrial dysfunction, and previous studies have shown that chondrocytes treated with IL-1β have increased mitochondrial superoxide production (Fig. 7a), likely from electron transport chain activity (ETC). This is further supported by increased membrane permeability from proteins such as PUMA (Supplementary Fig. S4a), which promotes mitochondrial membrane permeability through the stabilization of Bax. Together, these changes can lead to ETC dysfunction. Supporting this paradigm, antimycin A and rotenone, both ETC inhibitors, were able to reduce overall cellular ROS levels that were elevated in response to inflammation (Fig. 7b). Furthermore, previous studies have suggested that high oxidative stress can contribute to cell apoptosis as well. We utilized the Bax/Bac1 ratio as an apoptotic rheostat and show that IL-1β and BP both pushed the cell towards an apoptotic state (Fig. 7c, d). However, the use of NAC, an antioxidant, was able to protect the cell against an apoptotic shift. We then identified in vivo that MLI joints had higher expression levels of cleaved caspase-3, which is an apoptosis marker, as well as increased staining for γ-H2AX, which is a marker of DNA damage that can be associated with oxidative stress, suggesting that these in vitro findings likely extend in vivo as well (Fig. 7e, f).

Given that IL-1β treatment clearly caused mitochondrial dysfunction leading to oxidative stress, we wanted to determine if ETC inhibitors were effective at blocking the IL-1β and BP-induced inflammatory response by reducing oxidative stress. This would validate our findings of inflammation-induced oxidative stress by BP even if BP interfered with fluorescent assays. Mitochondrial ETC inhibitors antimycin A and rotenone treatment reduced expression of IL-1β protein and II-6 and MMP13 inflammatory gene expression (Fig. 7g, h, Supplementary Fig. S4b, c) induced by both IL-1β and BP, likely by decreasing ROS levels (Fig. 7e) in the cell. Likewise, MitOtempo, a mitochondrial ROS scavenger, rotenone, and antimycin A were also able to reduce iKB-ζ protein levels (Fig. 7i, Supplementary Fig. S4d). This corroborates previous findings wherein the use of an ETC inhibitor was able to reduce OA development in an intra-articular fracture model of OA. Finally, since we suspected oxidative stress to be an important mediator of catabolic gene expression in chondrocytes, we sought to determine if activation of the Nrf2 antioxidant system can reduce catabolic gene expression (Fig. 7a, b). Likewise, treatment with BP, likely by increasing oxidative stress, we wanted to explore the role of nitrosative stress. We used an Nrf2 pathway activator, Al-1, to display defective mitochondria. For the initial experiments using fluorescent readouts of redox states, we primarily utilized IL-1β since BP interfere with fluorescent assays. We show that chondrocytes treated with IL-1β have increased mitochondrial membrane permeability. Mitochondria are major ROS producers, especially when there is mitochondrial dysfunction, and previous studies have shown that chondrocytes treated with inflammatory stimulants display defective mitochondria. Mitochondria are major ROS producers, especially when there is mitochondrial dysfunction, and previous studies have shown that chondrocytes treated with inflammatory stimulants display defective mitochondria. For the initial experiments using fluorescent readouts of redox states, we primarily utilized IL-1β since BP interfere with fluorescent assays. We show that chondrocytes treated with IL-1β have increased mitochondrial membrane permeability. Mitochondria are major ROS producers, especially when there is mitochondrial dysfunction, and previous studies have shown that chondrocytes treated with inflammatory stimulants display defective mitochondria.

| Gene name | Primer sequence |
|-----------|-----------------|
| Actin (mouse) | F- CTAAGGCAACCGTGAAAGAG  
R- ACCAGAGGCTACAGGGACCA |
| IL-6 (mouse) | F- GAGGGATACATCTCCAACAGAC  
R- AAGTTGCAATGCTGTGGTCATA |
| MMP13 (mouse) | F- GCCAAGACTCTCCAACAGAC  
R- TCAGAGCGCAATTTTCTCC |
| IL-6 (human) | F- CCACTATGATCTCCTCTTC  
R- GCTTGCCTCATACCTCCT |
| MMP13 (human) | F- AATATCTGAAGCTGTCTCAAAAAA  
R- CAGAAGCTGTTCTCCTGAGAACAG |
| NFkB (mouse) | F- TCACTTCTGAGTACATCAC  
R- GGTGTTATTTTGAGTTTGGAG |
| NFkB (human) | F- CGGTTCCTGCACCACTGAG  
R- AGAAGAGGCCTGGCCTCCAT |
| Rankl (mouse) | F- TGAAGACACACTCTCCAGCTG  
R- CCCAATAATGGTTGACGT |
| Rankl (human) | F- CACTATAATGAGCACAGGAC  
R- GGTGATAGAATGGTGGATT |
| OPG (mouse) | F- GTTCAGCCAGAAGCACAAT  
R- CCACTCATAGTCTGCAAGAG |
| P16 (mouse) | F- AATCTGGCCGAGAAGAC  
R- GTGTCGAGGCGACTCCAT |
| P16 (human) | F- CCAAGACACAGAATAGGTA  
R- ACCAGGCTCAGTCCGGAAG |
| P21 (mouse) | F- TTGCCACAGAATAAAAGGTT  
R- TTGCTCCTGTCCGGGAAC |
| P21 (human) | F- TGGAGACTCTACAGGTCTGCAA  
R- GCCGTTTGGATGGTGAATAC |
| Lcn2 (mouse) | F- CCATCACAGTACAGAGAAGAACAT  
R- TCGATCCAGTGGCCAGAC |
| Acan (mouse) | F- CAAGGCTTACCCCAATGTT  
R- GAGGGTGGGAAGGACCATG |
| Nlrp3 (mouse) | F- CCGTGGAGACAGAGCTCCT  
R- GAGGCTCGAATGGTCTTAA |
| TRAP (mouse) | F- CACCTGCCAACCTGAATTGTT  
R- CACTGGGTCAGGAGTCTG |
| Admats4 (mouse) | F- CTTTCCTGCAATGTTAGTGG  
R- GAAAGTGTCCTGTGGTATGGA |
| Nqo1 (mouse) | F- TTATGGGCTCTGCGGAACAC  
R- GTTCCTGCTAATGGTCCAG |
| Ho1 (mouse) | F- GTCAGGAGCAAGGTCAGACA  
R- ATCAACATGGAGCTCCTAAA |
| iNOS (mouse) | F- TGATGGAGCAATGATATAGAC  
R- GCATCTGTCGAGTGATGAGCAA |
| NLRP3 (human) | F- CTTTCCTGCAATGTTAGTGG  
R- GCAGCAAACCTGGAAGAGGAG |
chondrocytes in vitro, we were able to show that IL-1β significantly increased NO production (Fig. 8c) but BP were unable to drive chondrocyte NO production (Fig. 8d), suggesting a mechanistic difference between BP and IL-1β in mediating NO production. Furthermore, we displayed that the effect observed with IL-1β was dependent upon the IKK2-NF-κB axis, since IKK2−/− chondrocytes had significantly lower NO production (Fig. 8c). To confirm that the elevated NO is originating from iNOS, we used L-NAME, a known iNOS inhibitor, to show that it is able to block the IL-1β mediated increase in NO (Fig. 8b).

NO can pathologically combine with superoxide from the mitochondria to form peroxynitrite, which is a known pathogenic ROS. Using a peroxynitrite-specific fluorescent probe, we display that peroxynitrite levels increase with IL-1β treatment in chondrocytes (Fig. 8e). Peroxynitrite reacts with proteins to form 3-nitrotyrosine (3-NT), which is an indicator of oxidative stress and damage that other groups have shown to be elevated in OA cartilage. We show that peroxynitrite and 3-NT levels elevated by IL-1β decreased with L-NAME treatment (Fig. 8e, Supplementary Fig. S5a), indicating that the NO arising from iNOS contributes to damaging peroxynitrite formation. Furthermore, since we suspected that NO combines with superoxide from the mitochondria, we show that mitoTEMPO, a mitochondria-targeted antioxidant, is able to decrease peroxynitrite formation (Fig. 8e).
Fig. 7 Inflammatory mediators promote apoptosis via mitochondrial oxidative stress. 

**a** Mitochondrial superoxide production was measured by MitoSox fluorescence under similar conditions (*****P < 0.0001). Bars are mean ± S.E.M. for n = 8 replicates from representative experiment. 

**b** Chondrocytes treated with IL-1β ± antimycin A (10 μmol·L⁻¹) or rotenone (100 μmol·L⁻¹) for 24 h. ROS levels in the cell were measured by DCFDA fluorescence (*****P < 0.0001). Bars represent mean ± S.D. for n = 8 replicates from representative experiments. 

**c, d** Chondrocytes treated with IL-1β or BP ± NAC (3 mmol·L⁻¹) for 24 h. Bax and Bcl2 ratios were then determined, normalizing to untreated cells (A: Untreated vs IL-1β ***P = 0.0005, IL-1β vs IL-1β + NAC *P = 0.0419, B: Untreated vs BP ***P = 0.0004, BP vs BP + NAC *P = 0.0118). Bars are mean ± S.E.M. from n = 5 independent experiments. 

**e, f** MLI surgery was performed on 12-week-old mice. Control sham surgery performed on contralateral knee. Joints were collected, embedded in paraffin and sectioned. IHC for cleaved caspase-3 and γ-H2AX was performed, with brown stain indicating positive cells. Representative images are displayed. 

**g, h** Chondrocytes were exposed to IL-1β or BP for 24 h ± rotenone (100 μmol·L⁻¹). Il6 and Mmp13 gene expression was measured by qPCR (****P < 0.0001). Bars represent mean ± S.D from representative experiment. 

**i, j** Chondrocytes were treated with IL-1β in the presence or absence of mitoTEMPO or Rotenone doses indicated. Western blotting was performed for IkB-ζ with actin used as control. Representative immunoblot is displayed. 

**k** Chondrocytes were exposed to IL-1β ± AI-1 (40 μmol·L⁻¹) for 24 h. Il6 gene expression was measured by qPCR. Bars represent mean ± S.D from n = 4 replicates. 

IkB-ζ promotes inflammatory chondrocytes and senescence

M Arra et al.
Nitrosative stress has different effects on inflammatory response in vitro and in vivo. a Chondrocytes were treated with IL-1β or BP for 24 h. Gene expression of iNos was measured by qPCR (F: Untreated vs IL-1β ***P = 0.0006, Untreated vs BP *P = 0.0201). b Chondrocytes were treated with IL-1β ± L-NAME (75 μmol·L⁻¹) for 24 h. NO levels were measured using DAF-FM-DA fluorescent probe. Bars represent mean ± SD from n = 8 replicates from representative experiment (****P<0.0001). c WT or IKK2−/− chondrocytes were treated with IL-1β for 24 h. Supernatant was collected and Greiss assay was carried out to measure NO production. (WT vs WT+IL-1β **P = 0.0026). Results are representative of at least three biological replicates. d Chondrocytes were transduced with pMX-GFP (WT) or pMX-IKK2ca. They were then treated with BP + S-Nitrosoglutathione (0.6 mmol·L⁻¹) or MitoTEMPO (0.5 mmol·L⁻¹) for 24 h. Peroxynitrite levels were measured using fluorescent sensor dye (Untreated vs IL-1β ****P<0.0001, IL-1β vs IL-1β + L-NAME ****P<0.0001, IL-1β vs IL-1β + MitoTEMPO *P = 0.045). Bars are mean ± SD from n = 4-6 replicates. f NF-κB luciferase reporter chondrocytes were treated with IL-1β ± SNOG or L-NAME for 24 h. Luciferase activity was measured as a readout of NF-κB activation (****P<0.0001). Bars are mean ± SD for n = 8 replicates from representative experiments. g Primary chondrocytes treated with IL-1β ± S-Nitrosoglutathione (0.6 mmol·L⁻¹) for 24 h. Western blot was performed for IkB-ζ. Representative immunoblot is displayed. h Chondrocytes were treated with IL-1β or BP ± SNOG (0.6 mmol·L⁻¹). Il6 gene expression measured by qPCR (B: IL-1β vs IL-1β + SNOG ****P = 0.0006, BP vs BP + SNOG *P = 0.04). Bars are mean ± SD of n = 4 independent experiments for Panel (h). i Chondrocytes treated with IL-1β or BP ± L-NAME (75 μmol·L⁻¹). Il6 gene expression was measured by qPCR. Data represent mean ± SD for replicates from one representative experiment out of three. j MLJ surgery was performed on 10-week-old mice. Control sham surgery was done on contralateral knee. Joints were collected, embedded in paraffin and sectioned. IHC for 3-nitrotyrosine was performed, with brown stain indicating positive cells. Representative images are displayed.
After observing that oxidative stress can drive senescence and SASP formation in an NF-κB-IκB-ζ mediated manner, we sought to interrogate the role of NO in this system. We treated chondrocytes with an NO donor, S-nitrosogluthathione (SNOG), which we confirmed was able to increase NO levels and 3-NT formation (Supplementary Fig. S5b, c). We observed that SNOG was pro-inflammatory, increasing NF-κB activation by IL-1β as well as protein levels of IκB-ζ (Fig. S8g, h). Furthermore, it was able to promote IL-1β and BP-induced expression of IL-6 (Fig. 8i). However, the use of iNOS inhibitor, L-NAME, was unable to decreased IL-1β and BP-induced expression of IL-6, suggesting that intrinsic NO levels are unlikely to be pro-inflammatory (Fig. 8j).

Since we had shown that oxidative stress promotes senescence and apoptosis, we wanted to determine if NO had similar pathologic effects. SNOG treatment in the setting of inflammatory stimuli leads to a significant increase in p21 expression, and a slight, although non-significant increase in p16 expression (Supplementary Fig. S5d, e). There was also a slight increase in Bax/Bcl2 ratio with SNOG treatment, though it was not statistically significant (Supplementary Fig. S5f). Furthermore, use of L-NAME, an iNOS inhibitor, was unable to reduce Bax/Bcl2 ratio caused by IL-1β or BP as NAC was able to (Fig. S5g, h), suggesting that a reduction of NO levels alone is insufficient to prevent apoptotic changes since there is still production of damaging oxidative species such as superoxide. Overall, these results suggest that addition of extra-physiological levels of NO with a donor can be pro-inflammatory but intrinsic NO production is not in and of itself pro-inflammatory.

We then sought to determine how these findings translate to the in vivo MLI model. Interestingly, we observed that MLI joints had consistently decreased 3-NT staining in the articular cartilage compared to sham joints, specifically with decreased staining in articular chondrocytes. This finding suggests that contrary to its role in other synovial joint components, 3-NT may not be a reliable marker of inflammation in articular chondrocytes in OA and that intrinsic NO may not be a pro-inflammatory mediator, as we observed in vitro. These results indicate the need for further research into the role of NO in the context of joint inflammation.

**DISCUSSION**

This work focuses on understanding the pathogenesis of OA through the lens of inflammation, senescence, and oxidative stress. The presence of mineral crystals and other matrix breakdown products in the synovial fluid has been noted in patients with OA and rheumatoid arthritis.19,20,22,27,28 However, it has been difficult to interpret the role of these particles in OA since it is unclear whether they are a product or drivers of the disease. While still unclear, we predict that they may arise from cartilage and bone erosions in part due to osteoclast activity. It is well recognized that patients with late-stage OA have subchondral sclerosis, though some groups have demonstrated that early OA may actually present with decreased subchondral bone volume.32 We show that post-traumatic OA (PTOA) joints display increased osteoclast numbers in the subchondral region. We also display that early OA joints have decreased subchondral bone, supporting the finding of increased bone breakdown early in disease, likely by osteoclasts. This leads to a dysregulation in bone remodeling, eventually leading to subchondral sclerosis seen in late-stage OA. Furthermore, we propose that chondrocyte-produced Rankl in response to inflammatory stimuli may be a significant osteoclast promoting force in regions adjacent to damaged cartilage in vivo. It is conceivable that “inflammatory chondrocytes” may recruit OCs and their progenitors to cartilage and adjacent bone matrices by Rankl secretion. Hence, subchondral bone-cartilage interaction is likely to be an important factor in OA disease progression, not simply a by-product of joint damage, as several groups have identified increased osteoclast numbers in subchondral bone,19–35 leading to attempts at OA therapy through modulation of subchondral bone remodeling.36

The activity of these inflammatory chondrocytes is driven by pathological mediators generated in the joint. Regardless of their source, BP are an example of one such mediator that drive a catabolic response in an NF-κB dependent manner, especially when they synergize with other inflammatory stimuli such as IL-1β. While the BP we utilized are not the same crystals found in the synovial fluid of human OA joints, we suspect that they can have similar pro-inflammatory effects as other inert crystal compounds. Given that other groups have already studied the effect of small crystals on the chondrocyte catabolic response,19,20,22,27,28 we wanted to take an approach that may be more physiologically relevant to disease states in which there is bony erosions or joint injuries leading to BP in the synovial space. We utilized real BP that vary in size and shape, as well as composed of diverse ECM compounds. Some physicians have endorsed the use of synovial lavage for the treatment of OA, although a meta-analysis displayed no benefit over placebo.59 However, this technique may be useful in patients with significant calcified compounds in their synovial space early in the disease and should be further studied.

We observed that BP and IL-1β generate a feed forward cycle of inflammation that contributes to the chronic inflammatory state present in OA joints that cannot be targeted by biologics such as anti-IL-1 or anti-TNF therapies, but can be addressed by targeting downstream signaling pathways such as the NF-κB pathway, which integrate signals downstream of several cytokines/receptors. However, given the indispensable role of NF-κB in normal physiologic pathways, sustained blockage of this pathway in humans is counterproductive. Instead, we identified IκB-ζ and NLRP3 inflammasome as downstream mediators of BP-induced inflammation, highlighting these as potential therapeutic targets.

We then provided evidence that inflammatory stimuli can promote senescence via activation of the NF-κB signaling pathway, which promotes various senescent programs such as the p16-Ink4a pathway, and also SASP expression via the NF-κB-IκB-ζ axis. We identified IκB-ζ at the intersection of inflammation and senescence given its ability to drive the expression of pro-inflammatory SASP genes in response to inflammatory stimuli such as BP or IL-1β. We also found that IκB-ζ appeared to be upstream of Nlrp3 and Rankl expression, further asserting its importance in the control of inflammatory, degenerative pathways in the joint. Given that the contribution of senescent chondrocytes to OA has been well-established, identifying factors such as IκB-ζ to attenuate the SASP production may be highly beneficial for preventing OA progression. In order to target IκB-ζ, we display that its expression is driven by a combination of inflammatory stimulation, oxidative and nitrosative stress to promote the expression of SASP genes, providing multiple avenues for reducing SASP expression.

Another interesting finding was that while IL-1β and BP are both pro-inflammatory, they have different effects on ROS and RNS. While IL-1β strongly induces ROS and RNS production, BP appear to be poor inducers of RNS, which may be explained by differences in their signaling pathways. Both induce NF-κb activation to drive inflammation, but they may have unique alternative pathway activation regarding nitrosative stressors. We identified the mitochondria as one source of oxidative stress activated by both players that appears to be a key driver of the inflammatory response through superoxide production. We further found that ETC inhibitors may be effective for treatment in the context of inflammation by blocking IκB-ζ expression, but that iNOS inhibitors were not effective. Hence, the role of RNS in the context of disease pathology requires further elucidation, especially in vivo, where we unexpectedly saw decreased 3-NT staining in the articular chondrocytes of OA joints. It is likely that NO can have pro-inflammatory functions at supraphysiological levels, which in conjunction with ROS species is likely to form molecules such as peroxynitrite, consistent with our finding that...
NO donors can exacerbate an inflammatory response in vitro by stabilizing IκB-ζ. This would corroborate some studies that have suggested that 3-NT levels are a pathological marker that is elevated in OA. However, we observed the opposite results in the chondrocytes in our animal model, which may be a function of the MLI mouse model of OA. Given that most of our work focuses on chondrocytes, it will be important to further understand the role of NO and 3-NT in other joint components such as synoviocytes, synovial macrophages and subchondral bone, which are intricately related to the articular cartilage, and may reconcile our work with prior studies displaying elevated 3-NT in OA joint synovial fluid, synovial cells and tissues. The lack of protection with iNOS inhibition in vitro further indicates that ROS species such as superoxide may be the primary inflammatory mediators and NO by itself is less important for chondrocyte inflammation. Another explanation is that exogenous NO donors produce NO throughout the cell, while physiologically, there are unique isoforms of iNOS that exist within subcellular compartments such as mitochondrial NO, iNOS, eNOS, and nNOS. Further supporting our findings that NO may not be pathologic, other groups have also displayed that NO can actually block mitochondrial ETC activity, leading to an antioxidant and protective effect by reducing superoxide levels. Given these findings, it is likely that NO has unique spatial and temporal effects within chondrocytes and needs to be better understood in the context of the OA joint through deletion of specific NOS subtypes and better NO detectors.

There are several experiments needed to further build upon the foundation of this work. First, we seek to develop a chondrocyte-specific Rankl knockout mouse to characterize the role of Rankl in OA progression and better appreciate the relationship between articular cartilage and subchondral bone, an area in need of significant exploration. A shortcomings of this project was the use of primarily murine chondrocytes, though we did utilize human OA cartilage for studying gene expression in order to validate our findings. The use of human synovial fluid to measure BP and the factors present in the fluid can provide insight into the role of these molecules in human disease. Another limitation of this project was the performance of in vitro experiments at 21% oxygen, which can influence the understanding of oxidative and nitrosative pathways, though we have displayed in a previous publication that inflammatory responses are similar at 21% oxygen and 4% oxygen cultures. Finally, it is important to use large animal models to validate our findings regarding oxidative stressors in the joint. The thickness of joint cartilage varies significantly from species to species, which may affect the ability of oxidative species to travel and affect adjacent cellular compartments. The use of pig and bovine models to validate our results will provide greater insight into the role of subchondral remodeling as well as oxidative stress in the joint.

**MATERIALS AND METHODS**

**Animal models**

All animal models were bred on a C57/BL6 background. 10-week-old wild type mice were used for PTOA models. For isolation of primary chondrocytes, WT, IKK2ox/ox, Nkbiaox/ox and Nlrp3 KO pups aged P1-P3 were used. Recombination was induced in Aggrecan-ERT2-cre mouse model by feeding tamoxifen chow for 2 weeks. IKK2ca flox/flox mice were crossed with Aggrecan-ERT2-cre mice to express IKK2ca in chondrocytes in mature mice at age 10 weeks. All experiments were performed using littermate controls. Mice were housed at the Washington University School of Medicine facility. All experimental protocols were carried out in accordance with the ethical guidelines approved by the Washington University School of Medicine Institutional Animal Care and Use Committee. Mice were housed in barrier facility at five or less per cage at 24–26 degrees Celsius with humidity ranging between 30%–60% with 12 h light/dark cycles switching at 6 pm.

**Meniscal ligamentous injury model**

The MLI model was utilized to induce post-traumatic OA in mice at 12 weeks of age. Medial ligament and meniscus were transected in the right legs of mice, with sham surgery performed on the contralateral knee joint. Sham surgery involves cutting skin superficially and suturing without transecting ligaments in the knee joint. Mice were sacrificed and limbs were harvested for further analysis.

**Cell culture**

Primary chondrocytes were harvested from sterna and ribs of P1-P3 mice using sequential digestion with pronase (2 mg·mL⁻¹, PRON-RO, Roche) at 37 degrees, collagenase D (3 mg·mL⁻¹, COLLD-RO, Roche) two times at 37 degrees, and cultured in DMEM (Life Technologies, USA) containing 10% FBS and 1% penicillin/streptomycin (Thermo Fisher). Primary chondrocytes are not passaged and experiments are completed within 5 days of isolation from mice. Primary macrophages (osteoclast precursors) were harvested from long bones of WT mice and cultured in M-CSF overnight before being added to chondrocyte cultures. Cells were incubated with recombinant IL-1β (10 ng·mL⁻¹), iNOS inhibitor SC-514 (10 μmol·L⁻¹), BP (1 mg·mL⁻¹). Plat-E cells were used to generate retroviral particles.

**Bone particle generation**

BP were obtained from porcine long bones. First, porcine bones were obtained from butcher shops. Then bone surfaces were extensively washed with PBS and 70% ethanol. The cortical bone was then cut using an automatic low speed bone saw (Buehler IsoMet) on the ephiysseal surfaces. The bone dust produced was collected as BP. The BP were then thoroughly washed with sterile PBS, autoclaved and stored at 70% ethanol at 4 degrees. Prior to use, BP were washed in sterile PBS to remove ethanol and re-suspended in PBS. After shaking tube containing particles, large orifice pipette tips were used to pick up BP from the surface of the solution and added to chondrocyte cell culture.

**Retroviral and adenoviral infection**

Adenovirus was utilized for deleting genes from cells with floxed genes. Cells were infected with commercially obtained adenoviral-GFP (VVC-U of Iowa 4) and adenoviral-cre (VVC-U of Iowa 3554) at an MOI of 10 in the presence of 5 μg·mL⁻¹ of polybrene (TR-1003, Sigma) in 5% FBS-containing DMEM. After 24 h, media was switched to DMEM ± 10% FBS. Retrovirus was utilized to infect chondrocytes with GFP, IKK2ca, or IKK2-KD. Retrovirus was generated by transfecting PLAT-E cells with pMX-GFP, pMX-IKK2ca or pMX-IKK2-KD constructs using X-tremegene. Cells were incubated with recombinant IL-1β (10 ng·mL⁻¹), iNOS inhibitor SC-514 (10 μmol·L⁻¹), BP (1 mg·mL⁻¹). Plat-E cells were used to generate retroviral particles.
Quantitative PCR
Trizol (Sigma) and Chloroform at a ratio of 0.2:1 were added to samples, followed by centrifugation at 12,000 x g for 15 min. Aqueous layer was collected and equal amount of 70% ethanol was added. RNA was then isolated from this fraction using PureLink RNA mini kit (Cat# 12183025, Ambion, Grand Island, NY, USA). cDNA was prepared using High Capacity cDNA Reverse Transcription kit (Cat# 4368814, Applied Biosystems). qPCR was carried out on BioRad CFX96 real time system using iTaq universal SYBR green super-mix (Cat#1725120, BioRad, Hercules, CA, USA). Actin was used to normalize mRNA expression.

IL-1β ELISA
Chondrocytes were cultured with BP and/or IL-1β. Supernatant was collected for ELISA. Supernatant was added to IL-1β-coated ELISA plates and incubated overnight at 4 degrees. Samples were washed with PBST and biotin-conjugated secondary antibody was added to plates for 1 h at room temperature. After washing again, streptavidin-HRP was added to wells for 1 h, washed, and TMB substrate was added. Reaction was stopped prior to reading.

Histology
Knee joints were isolated from mice and fixed in 10% neutral buffered formalin (HT501128, Sigma) for 24 h followed by decalcification in Immunocal (StatLab, McKinney, TX) for 3 days. Samples were then embedded in paraffin before cutting 5 μm-thick sections. Unstained sections were utilized for IHC. Remaining sections were stained with safranin-O/fast green stain. Severity of OA was graded by OARSI scoring. Reviewers were blinded to treatment conditions of slides being scored.

Immunohistochemistry
Sections were deparaffinized and rehydrated using three changes of xylolenes followed by ethanol gradient. Antigen retrieval was performed using citrate solution pH 6.0 at 60 °C overnight, followed by blocking for 1 h using blocking solution (10% goat serum in PBS, 1% tween-20, 1% BSA). Sections were then incubated with primary antibody diluted in DAKO dilution solution (S3022, Agilent, Santa Clara, CA) overnight at 4 degrees then washed and incubated with biotin-conjugated secondary antibody (BP-1100, Vector Biolabs, Burlington, CA) at room temperature for 2 h. Sections were washed and incubated with streptavidin-HRP using Vectastain ABC-HRP (PK-4000, Vector Laboratories, Burlington, CA) for 20 min. After washing, sections were developed using DAB peroxidase kit (SK4100, Vector Laboratories, Burlington, CA). Anti-p16-ink4a (PA5-20379, Thermo Fisher), anti-IκB-ζ (NBP-89835, Novus Biologicals, Centennial, CO), anti-3-NT (06-284, Millipore Sigma, Burlington, CA), cleaved caspase-3 (9661 S, CST, Danvers, MA), and Y-H2AX (2577 S, CST, Danvers, MA) were used in blocking solution.

ROS and RNS assays
ROS species in the cell were measured using H2, DCF-DA fluorescent dye (Cat#D6883, Sigma) and RNS species were measured using H2-DAF-FM-DH fluorescent dye in 96 well plate format. Cells were pre-treated 24 h with appropriate treatment conditions in DMEM media. Next, cells were washed and incubated with 5 μmol-L−1 DCFDA or DAFFM-DA dissolved in PBS for 30 min, washed several times with PBS and placed back in the incubator. After 1 h, fluorescence was measured on microplate reader at Ex/Em 495/518.

Peroxytnitrite assay
Peroxytnitrite was measured in the cell using Dax-J2 PON fluorescent dye (Abcam ab233469) in 96 well plate format. Cells were pre-treated for 24 h with appropriate treatment conditions in DMEM media. Cells were incubated with 10 μmol-L−1 Dax-J2 PON in media for 30 min. Next, cells were washed several times with PBS and placed back in the incubator. After 1 h, fluorescence was measured on microplate reader at Ex/Em 495/518.

3-Nitrotyrosine ELISA
3-Nitrotyrosine adduct formation on proteins in the cell were measured by ELISA kit (Abcam, ab116691tab). Chondrocytes were cultured with IL-1β for 24 h and 100 μL of supernatant was used undiluted in the assay, performed in technical replicates for each biological sample.

Greiss assay
Supernatant from chondrocyte culture was collected under various conditions. Greiss assay was performed using assay kit (G7921, Thermo Fisher) in microplate format, using 150 μL of supernatant per well. Culture media was used as control for background correction.

Micro computed tomography (μCT)
Intact knee joints were harvested, fixed overnight in 10% neutral buffered formalin (HT501128, Sigma) then washed with Phosphate Buffer Saline (PBS) three times and transferred to 70% ethanol (v/v). Bones were scanned at a resolution of 20 μm, slice increment 10 μm, voltage 55 kV, current 145 μA and exposure time of 200 ms and 3D images were constructed using Scanco Medical micro-CT systems (Scanco, Wayne, PA, USA) at Washington University in St. Louis (St. Louis, MO).

RNA sequencing
Primary chondrocytes were cultured ± IL-1β (10 ng·mL−1) for 24 h. RNA was collected and samples were prepared according to library kit manufacturer’s protocol, indexed, pooled, and sequenced on an Illumina HiSeq. Basecalls and demultiplexing were performed with Illumina’s bcl2fastq software and a custom python demultiplexing program with a maximum of one mismatch in the indexing read. RNA-Seq reads were then aligned to the Ensembl release 76 primary assembly with STAR version 2.5.1a. Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.6-p5. Isoform expression of known Ensembl transcripts were estimated with Salmon version 0.8.2. Sequencing performance was assessed for the total number of aligned reads, the total number of uniquely aligned reads, and features detected. The ribosomal fraction, known junction saturation, and read distribution over known gene models were quantified with RSeQC version 2.6.2.

All gene counts were then imported into the R/Bioconductor package EdgeR and TMM normalization size factors were calculated to adjust for samples for differences in library size. Ribosomal genes and genes not expressed in the smallest group size minus one sample greater than one count-per-million were excluded from further analysis. The TMM size factors and the matrix of counts were then imported into the R/Bioconductor package Limma. Weighted likelihoods based on the observed mean-variance relationship of every gene and sample were then calculated for all samples with the voomWithQualityWeights. The performance of all genes was assessed with plots of the residual standard deviation of every gene to their average log-count with a robustly fitted trend line.
of the residuals. Differential expression analysis was then performed to analyze for differences between conditions and the results were filtered for only those genes with Benjamini-Hochberg false-discovery rate adjusted P-values less than or equal to 0.05.

For each contrast extracted with Limma, global perturbations in known Gene Ontology (GO) terms, MSigDb, and KEGG pathways were detected using the R/Bioconductor package GAGE to test for changes in expression of the reported log 2-fold-changes reported by Limma in each term versus the background log 2-fold-changes of all genes found outside the respective term. The R/Bioconductor package heatmap3 was used to display heatmaps across groups of samples for each GO or MSigDb term with a Benjamini-Hochberg false-discovery rate adjusted P-value less than or equal to 0.05. Perturbed KEGG pathways where the observed log 2-fold-changes of genes within the term were significantly perturbed in a single-direction versus background or in any direction compared to other genes within a given term with P-values less than or equal to 0.05 were rendered as annotated KEGG graphs with the R/Bioconductor package Pathview.

Statistical analysis

Experiments were routinely carried out in replicates, unless otherwise stated. GraphPad Prism was employed for all experiments using appropriate statistical test. Multiple treatments were analyzed by One-way ANOVA followed by Tukey's test multiple comparisons test. Student's t test was used for comparing two groups. Age and sex-matched mice were used. Values are expressed as mean ± SD of representative experiment out of at least three independent experiments. P-values are indicated where applicable.

ACKNOWLEDGEMENTS

This work was supported by NIH/NIAMS R01-AR049192, R01-AR054326 (to YA), Biomedical grant from Shriners Hospital for Children (YAJ), P30 AR074992 NH Core Center for Musculoskeletal Biology and Medicine (to YA) and NIH/NIAMS R01-AR064755 and R01-AR068972 (to GM).

AUTHOR CONTRIBUTIONS

M.A., G.S., G.M., Y.A. participated in study design and troubleshooting; M.A., G.S., G.M., Y.A. wrote the manuscript; M.A. and Y.A. wrote the manuscript; G.S. and G.M. participated in study design and troubleshooting; M.A., G.S., G.M., Y.A. participated in study design and troubleshooting; M.A., G.S., G.M., Y.A. performed to analyze for differences between conditions and the results were filtered for only those genes with Benjamini-Hochberg false-discovery rate adjusted P-values less than or equal to 0.05.

REFERENCES

1. Zhang, Y. & Jordan, J. M. Epidemiology of osteoarthritis. Clin. Geriatr. Med. 26, 355–369 (2010).
2. Wallace, I. J. et al. Knee osteoarthritis has doubled in prevalence since the mid-20th century. Proc. Natl. Acad. Sci. USA 114, 9332–9336 (2017).
3. Turkiewicz, A. et al. Current and future impact of osteoarthritis on health care: a population-based study with projections to year 2032. Osteoarthr. Cartil. 22, 1826–1832 (2014).
4. Golding, M. B. & Otero, M. Inflammation in osteoarthritis. Curr. Opin. Rheumatol. 23, 471–478 (2011).
5. Sokolove, J. & Lepus, C. M. Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations. Ther. Adv. Musculoskelet. Dis. 5, 77–94 (2013).
6. Rogers, E. L., Reynard, L. N. & Loughlin, J. The role of inflammation-related genes in osteoarthritis. Osteoarthr. Cartil. 23, 1933–1938 (2015).
7. Benenbaum, F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthr. Cartil. 21, 16–21 (2013).
8. Zhang, Q., Lenardo, M. J. & Baltimore, D. 30 years of NF-kappaB: a blossoming of relevance to human pathobiology. Cell. 168, 37–57 (2017).
9. Rigoglou, S. & Papavassiliou, A. G. The NF-kappaB signalling pathway in osteoarthritis. Int. J. Biochem. Cell Biol. 45, 2580–2584 (2013).
10. Loeser, R. F. Aging and osteoarthritis: the role of chondrocyte senescence and aging changes in the cartilage matrix. Osteoarthr. Cartil. 17, 971–979 (2009).
11. Martin J. A., Brown T. D., Heiner A. D., Buckwalter J. A. Chondrocyte senescence, joint loading and osteoarthritis. Clin. Orthop. Relat. Res. 427, 596–5103 (2004).
12. Toh, W. S. et al. Cellular senescence in aging and osteoarthritis. Acta Orthop. 87, 6–14 (2016).
13. Leon, O. H., David, N., Campisi, J. & Eissfeld, J. H. Senescent cells and osteoarthritis: a painful connection. J. Clin. Invest. 128, 1229–1237 (2018).
14. Kang D. et al. Stress-activated miR-204 governs senescent phenotypes of chondrocytes to promote osteoarthritis development. Sci. Transl. Med. 11, 1–14 (2019).
15. Vinater, C., Dominguez, E., Guicheux, J. & Carames, B. Role of the inflammation-autophagy-senescence integrative network in osteoarthritis. Front. Physiol. 9, 706 (2018).
16. Coryell, P. R., Diekman, B. O. & Loeser, R. F. Mechanisms and therapeutic implications of cellular senescence in osteoarthritis. Nat. Rev. Rheumatol. 17, 47–57 (2021).
17. Lepetos, P. & Papavassiliou, A. G. ROS/oxidative stress signaling in osteoarthritis. Biochim. Biophys. Acta 1862, 576–591 (2016).
18. Kang, C. Senolytics and senostatics: a two-pronged approach to target cellular senescence for delaying aging and age-related diseases. Mol. Cells. 42, 821–827 (2019).
19. Wu, C. W., Terkeltaub, R. & Kalunian, K. C. Calcium-containing crystals and osteoarthritis: implications for the clinician. Curr. Rheumatol. Rep. 7, 213–219 (2005).
20. Cheung, H. S. Role of calcium-containing crystals in osteoarthritis. Front. Biosci. 10, 1336–1340 (2005).
21. Jaovisidha, K. & Rosenthal, A. K. Calcium crystals in osteoarthritis. Curr. Opin. Rheumatol. 14, 298–302 (2002).
22. Ha, H. K. et al. Articular cartilage calcification in osteoarthritis: insights into crystal-induced stress. Arthritis Rheum. 63, 10–18 (2011).
23. Donnell, S. Subchondral bone remodelling in osteoarthritis. EFORT Open Rev. 4, 221–229 (2019).
24. Funck-Brentano, T. & Cohen-Solal, M. Subchondral bone and osteoarthritis. Curr. Opin. Rheumatol. 27, 420–426 (2015).
25. Henrotin, Y., Peisse, L. & Sanchez, C. Subchondral bone in osteoarthritis: state-of-the art and perspectives. Biomed. Mater. Eng. 19, 311–316 (2009).
26. Wang, B., Jin, H., Shu, B., Mira, R. & Chen, D. Chondrocytes-specific expression of osteoprotegerin modulates osteoclast formation in metaphyseal bone. Sci. Rep. 5, 13667 (2015).
27. Ha, H. K. et al. Pathogenic role of basic calcium phosphate crystals in destructive arthropathies. PLoS One. 8, e57352 (2013).
28. Ha, H. K., So, A., Liote, F. & Bussos, N. Basic calcium phosphate crystals induce NLRP3 inflammasome activation: the in vitro and in vivo face to face. Proc. Natl. Acad. Sci. USA 108, E1361 (2011).
29. Sofat, N. Analysing the role of endogenous matrix molecules in the development of osteoarthritis. Int. J. Exp. Pathol. 90, 463–479 (2009).
30. Nalbant, S. et al. Synovial fluid features and their relations to osteoarthritis severity: new findings from sequential studies. Osteoarthr. Cartil. 11, 50–54 (2003).
31. Evans, C. H., Mazzocchi, R. A., Nelson, D. D. & Rubash, H. E. Experimental arthritis induced by intraarticular injection of algogenic cartilaginous particles into rabbit knees. Arthritis Rheum. 27, 200–207 (1984).
32. Kwan Tat, S., Lajunnesse, D., Pelletier, J. P. & Martel-Pelletier, J. Targeting subchondral bone for treating osteoarthritis: what is the evidence? Best. Pr. Res. Clin. Rheumatol. 24, 51–70 (2010).
33. Bapat, S., Hubbard, D., Munjal, A., Hunter, M. & Fulzele, S. Pros and cons of mouse models for studying osteoarthritis. Clin. Transl. Med. 7, 36 (2018).
34. Ara, M. et al. LDHA-mediated ROS generation in chondrocytes is a potential therapeutic target for osteoarthritis. Nat. Commun. 11, 3427 (2020).
35. Kobayashi, Y., Udagawa, N. & Takahashi, N. Action of RANKL and OPG for osteoclastogenesis. Crit. Rev. Eukaryot. Gene Expr. 19, 61–72 (2009).
36. Mahon, O. R. & Dunne, A. Disease-associated particulates and joint inflammation: mechanistic insights and potential therapeutic targets. Front. Immunol. 9, 1145 (2018).
37. Jo, E. K., Kim, J. K., Shin, D. M. & Sakasaka, C. Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol. Immunol. 13, 148–159 (2016).
38. Willems, M., Dubois, N., Musumeci, L., Bours, V. & Robe, P. A. IkappaBzeta: an emerging player in cancer. Oncotarget. 7, 66310–66322 (2016).
39. Choi, M. C., MaruYama, T., Chun, C. H. & Park, Y. Alleviation of murine osteoarthritis by cartilage-specific deletion of IkappaBzeta. *Arthritis Rheumatol.* **70**, 1440–1449 (2018).

40. Hou, A. et al. Cellular senescence in osteoarthritis and anti-aging strategies. *Mech. Ageing Dev.* **175**, 83–87 (2018).

41. McCulloch, K., Lithenfeld, G. J. & Rai, T. S. Cellular senescence in osteoarthritis pathology. *Aging Cell.* **16**, 210–218 (2017).

42. Philipot, D. et al. p16INK4a and its regulator miR-24 link senescence and chondrocyte terminal differentiation-associated matrix remodeling in osteoarthritis. *Arthritis Res. Ther.* **16**, R58 (2014).

43. Che H., et al. p16 deficiency attenuates intervertebral disc degeneration by adjusting oxidative stress and nucleus pulposus cell cycle. *Elife.* **9**, e52570 (2020).

44. Kim, E. C. & Kim, J. R. Senotherapeutics: emerging strategy for healthy aging and age-related disease. *BMB Rep.* **52**, 47–55 (2019).

45. Drevet, S., Gavazzi, G., Grange, L., Dupuy, C. & Lardy, B. Reactive oxygen species and NADPH oxidase 4 involvement in osteoarthritis. *Exp. Gerontol.* **111**, 107–117 (2018).

46. van Dalen, S. C. M. et al. The role of NOX2-derived reactive oxygen species in collagenase-induced osteoarthritis. *Osteoarthr. Cartil.* **26**, 1722–1732 (2018).

47. Zhao, R. Z., Jiang, S., Zhang, L. & Yu, Z. B. Mitochondrial electron transport chain, ROS generation and uncoupling (Review). *Int. J. Mol. Med.* **44**, 3–15 (2019).

48. Blanco, F. J., Rego, I. & Ruiz-Romero, C. The role of mitochondria in osteoarthritis. *Nat. Rev. Rheumatol.* **7**, 161–169 (2011).

49. Hikisz, P. & Kilianska, Z. M. PUMA, a critical mediator of cell death—one decade on from its discovery. *Cell Mol. Biol. Lett.* **17**, 646–669 (2012).

50. Zhu, L. et al. Curcumin triggers apoptosis via upregulation of Bax/Bcl-2 ratio and caspase activation in SW872 human adipocytes. *Mol. Med. Rep.* **12**, 1151–1156 (2015).

51. Salakou, S. et al. Increased Bax/Bcl-2 ratio up-regulates caspase-3 and increases apoptosis in the thymus of patients with myasthenia gravis. *Vivo.* **21**, 123–132 (2007).

52. Coleman M. C., et al. Targeting mitochondrial responses to intra-articular fracture to prevent posttraumatic osteoarthritis. *Sci. Transl. Med.* **10**, 1–14 (2018).

53. Pacher, P., Beckman, J. S. & Liaudet, L. Nitric oxide and peroxynitrite in health and disease. *Physiol. Rev.* **87**, 315–424 (2007).

54. Loeser, R. F., Carlson, C. S., Del Carlo, M. & Cole, A. Detection of nitrotyrosine in aging and osteoarthritic cartilage: Correlation of oxidative damage with the presence of interleukin-1beta and with chondrocyte resistance to insulin-like growth factor 1. *Arthritis Rheum.* **46**, 2349–2357 (2002).

55. Sun Q., et al. Parathyroid hormone attenuates osteoarthritis pain by remodeling subchondral bone in mice. *Elife.* **10**, e66532 (2021).

56. Li, X. et al. Knee loading inhibits osteoclast lineage in a mouse model of osteoarthritis. *Sci. Rep.* **6**, 24668 (2016).

57. Bertuglia, A. et al. Osteoclasts are recruited to the subchondral bone in naturally occurring post-traumatic equine carpal osteoarthritis and may contribute to cartilage degradation. *Osteoarthr. Cartil.* **24**, 555–566 (2016).

58. Zhu, X., Chan, Y. T., Yung, P. S. H., Tuan, R. S. & Jiang, Y. Subchondral bone remodeling: a therapeutic target for osteoarthritis. *Front. Cell Dev. Biol.* **8**, 607764 (2020).

59. Avouac, J., Vicaut, E., Bardin, T. & Richette, P. Efficacy of joint lavage in knee osteoarthritis: meta-analysis of randomized controlled studies. *Rheumatol. (Oxf).* **49**, 334–340 (2010).

60. Villanueva, C. & Giulivi, C. Subcellular and cellular locations of nitric oxide synthase isoforms as determinants of health and disease. *Free Radic. Biol. Med.* **49**, 307–316 (2010).

61. Dikalov, S. I., Mayorov, V. I. & Panov, A. V. Physiological levels of nitric oxide diminish mitochondrial superoxide. potential role of mitochondrial dinitrosyl iron complexes and nitrosothiols. *Front. Physiol.* **8**, 907 (2017).

62. Wink, D. A. et al. Mechanisms of the antioxidant effects of nitric oxide. *Antioxid. Redox Signal.* **3**, 203–213 (2001).